187 related articles for article (PubMed ID: 30141208)
1. Association of genetic variation of the six gene prognostic model for castration-resistant prostate cancer with survival.
Xie W; Stopsack KH; Drouin SJ; Fu H; Pomerantz MM; Mucci LA; Lee GM; Kantoff PW
Prostate; 2019 Jan; 79(1):73-80. PubMed ID: 30141208
[TBL] [Abstract][Full Text] [Related]
2. Germline genetic variation in JAK2 as a prognostic marker in castration-resistant prostate cancer.
Zhang BY; Riska SM; Mahoney DW; Costello BA; Kohli R; Quevedo JF; Cerhan JR; Kohli M
BJU Int; 2017 Mar; 119(3):489-495. PubMed ID: 27410686
[TBL] [Abstract][Full Text] [Related]
3. A 2-Gene Panel Derived From Prostate Cancer-Enhanced Transcripts in Whole Blood Is Prognostic for Survival and Predicts Treatment Benefit in Metastatic Castration-Resistant Prostate Cancer.
Heck MM; Thalgott M; Schmid SC; Oh WK; Gong Y; Wang L; Zhu J; Seitz AK; Porst D; Höppner M; Retz M; Gschwend JE; Nawroth R
Prostate; 2016 Sep; 76(13):1160-8. PubMed ID: 27198487
[TBL] [Abstract][Full Text] [Related]
4. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study.
Ross RW; Galsky MD; Scher HI; Magidson J; Wassmann K; Lee GS; Katz L; Subudhi SK; Anand A; Fleisher M; Kantoff PW; Oh WK
Lancet Oncol; 2012 Nov; 13(11):1105-13. PubMed ID: 23059047
[TBL] [Abstract][Full Text] [Related]
5. Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: A tertiary academic center experience.
Afshar M; Evison F; James ND; Patel P
Urol Oncol; 2015 Aug; 33(8):338.e1-7. PubMed ID: 26059077
[TBL] [Abstract][Full Text] [Related]
6. Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer.
Binder M; Zhang BY; Hillman DW; Kohli R; Kohli T; Lee A; Kohli M
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27409606
[TBL] [Abstract][Full Text] [Related]
7. Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in Sweden.
Aly M; Leval A; Schain F; Liwing J; Lawson J; Vágó E; Nordström T; Andersson TM; Sjöland E; Wang C; Eloranta S; Akre O
Scand J Urol; 2020 Apr; 54(2):115-121. PubMed ID: 32266854
[No Abstract] [Full Text] [Related]
8. In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database.
Whitney CA; Howard LE; Posadas EM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
Eur Urol Focus; 2017 Oct; 3(4-5):480-486. PubMed ID: 28753787
[TBL] [Abstract][Full Text] [Related]
9. Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?
Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Divers CH; Valderrama A; Freedland SJ
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):380-384. PubMed ID: 27377207
[TBL] [Abstract][Full Text] [Related]
10. Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes.
Wright JL; Kwon EM; Ostrander EA; Montgomery RB; Lin DW; Vessella R; Stanford JL; Mostaghel EA
Cancer Epidemiol Biomarkers Prev; 2011 Apr; 20(4):619-27. PubMed ID: 21266523
[TBL] [Abstract][Full Text] [Related]
11. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.
Hammerich KH; Donahue TF; Rosner IL; Cullen J; Kuo HC; Hurwitz L; Chen Y; Bernstein M; Coleman J; Danila DC; Metwalli AR
Urol Oncol; 2017 Jul; 35(7):460.e21-460.e28. PubMed ID: 28410987
[TBL] [Abstract][Full Text] [Related]
12. C-Reactive Protein is a Prognostic Marker for Patients with Castration-Resistant Prostate Cancer.
Liao SG; Cheng HH; Lei Y
Oncol Res Treat; 2016; 39(5):266-71. PubMed ID: 27174032
[TBL] [Abstract][Full Text] [Related]
13. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer.
Huang X; Yuan T; Liang M; Du M; Xia S; Dittmar R; Wang D; See W; Costello BA; Quevedo F; Tan W; Nandy D; Bevan GH; Longenbach S; Sun Z; Lu Y; Wang T; Thibodeau SN; Boardman L; Kohli M; Wang L
Eur Urol; 2015 Jan; 67(1):33-41. PubMed ID: 25129854
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms of CYP17A1 in steroidogenesis pathway are associated with risk of progression to castration-resistant prostate cancer in Japanese men receiving androgen deprivation therapy.
Yamada T; Nakayama M; Shimizu T; Nonen S; Nakai Y; Nishimura K; Fujio Y; Okuyama A; Azuma J; Nonomura N
Int J Clin Oncol; 2013 Aug; 18(4):711-7. PubMed ID: 22714708
[TBL] [Abstract][Full Text] [Related]
15. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate.
Yamamoto A; Kato M; Matsui H; Ishida R; Kimura T; Funahashi Y; Sassa N; Matsukawa Y; Kamihira O; Hattori R; Gotoh M; Tsuzuki T
Int J Clin Oncol; 2018 Jun; 23(3):584-590. PubMed ID: 29397469
[TBL] [Abstract][Full Text] [Related]
17. Commentary on "Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study." Schutz FA, Pomerantz MM, Gray KP, Atkins MB, Rosenberg JE, Hirsch MS, McDermott DF, Lampron ME, Lee GS, Signoretti S, Kantoff PW, Freedman ML, Choueiri TK, Dana-Farber Cancer Institute, Boston, MA 02115.: Lancet Oncol 2013;14(1):81-87. [Epub 2012 Dec 7]. doi: 10.1016/S1470-2045(12)70517-X. Erratum in, Lancet Oncol 2013;14(3):e89.
Meng M
Urol Oncol; 2014 May; 32(4):512-3. PubMed ID: 24767687
[TBL] [Abstract][Full Text] [Related]
18. Assessment of a Clinical Trial-Derived Survival Model in Patients With Metastatic Castration-Resistant Prostate Cancer.
Coquet J; Bievre N; Billaut V; Seneviratne M; Magnani CJ; Bozkurt S; Brooks JD; Hernandez-Boussard T
JAMA Netw Open; 2021 Jan; 4(1):e2031730. PubMed ID: 33481032
[TBL] [Abstract][Full Text] [Related]
19. Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer.
Chen WS; Feng EL; Aggarwal R; Foye A; Beer TM; Alumkal JJ; Gleave M; Chi KN; Reiter RE; Rettig MB; Evans CP; Small EJ; Sharifi N; Zhao SG
Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):316-323. PubMed ID: 31745256
[TBL] [Abstract][Full Text] [Related]
20. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
